Evaluation of Exenatide in Patients With Diabetic Neuropathy
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study will look at whether or not the medication exenatide improves signs and symptoms
of diabetic peripheral neuropathy in people with type 2 diabetes and mild to moderate
diabetic peripheral neuropathy.
Phase:
N/A
Details
Lead Sponsor:
University of Michigan
Collaborators:
Amylin Pharmaceuticals, LLC. Eli Lilly and Company